The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis

Drug Resistance Updates

Volumn 9, Issue 4-5, 2006, Pages 227-246

  Assaraf, Yehuda G ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

ABC transporters; Antifolates; Breast cancer resistance protein; Cellular folate pools; Chemotherapy; Drug resistance; Efflux pumps; Folate homeostasis; Folates; Multidrug resistance proteins

Indexed keywords

ABC TRANSPORTER; AMINOPTERIN; BGC 945; BREAST CANCER RESISTANCE PROTEIN; EDATREXATE; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID ANTAGONIST; GEFITINIB; GW 1843; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; NOLATREXED; OSI 7904L; PEMETREXED; PIRITREXIM; RALTITREXED; TRIMETREXATE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMICAL MODIFICATION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TRANSPORT; FOLATE HOMEOSTASIS; HOMEOSTASIS; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MULTIDRUG RESISTANCE; NONHUMAN; POLYGLUTAMYLATION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; FOLIC ACID; FOLIC ACID ANTAGONISTS; HOMEOSTASIS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 33750975065     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2006.09.001     Document Type: Article

References (148)

1. Abdul-Ghani R., Serra V., Gyorffy B., Jurchott K., Solf A., Dietel M., and Schafer R. The PI3K inhibitor LY294002 blocks drug export from colon carcinoma cells overexpressing MRP1. Oncogene 25 (2006) 1743-1752
2. Allegra C.J., Chabner B.A., Drake J.C., Lutz R., Rodbard D., and Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 260 (1985) 9720-9726
3. Allegra C.J., Hoang K., Yeh G.C., Drake J.C., and Baram J. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J. Biol. Chem. 262 (1987) 13520-13526
4. Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., and Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58 (1999) 5337-5339
5. Assaraf Y.G., and Schimke R.T. Identification of methotrexate transport deficiency in mammalian cells using fluoresceinated methotrexate and flow cytometry. Proc. Natl. Acad. Sci. USA 84 (1987) 7154-7158
6. Assaraf Y.G., Molina A., and Schimke R.T. Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug resistance phenotype. J. Natl. Cancer Inst. 81 (1989) 290-294
7. Assaraf Y.G., Molina A., and Schimke R.T. Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate. J. Biol. Chem. 264 (1989) 18326-18334
8. Assaraf Y.G., and Slotky J.I. Characterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine. J. Biol. Chem. 268 (1993) 4556-4566
9. Assaraf Y.G., and Goldman I.D. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells 272 (1997) 17460-17466
10. Assaraf Y.G., Babani, and Goldman I.D. Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in Chinese hamster ovary cells. J. Biol. Chem. 273 (1998) 8106-8111
11. Assaraf Y.G., Rothem L., Hooijberg J.H., Stark M., Ifergan I., Kathmann I., Dijkmans B.A.C., Peters G.J., and Jansen G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem. 278 (2003) 6680-6686
12. Assaraf Y.G., Ifergan I., Kadry W., and Pinter R.Y. Computer modeling of antifolate inhibition of folate metabolism using hybrid functional petri nets. J. Theor. Biol. 240 (2006) 637-647
13. Baggott J.E., Vaughn W.H., and Hudson B.B. Inhibition of 5-aminoimidazole-4-carboxamide-ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide-riboside and ribotide. Biochem. J. 236 (1986) 193-200
14. Baugh C.M., Krumdieck C.L., and Nair M.G. Poly-γ-glutamyl metabolites of methotrexate. Biochim. Biophys. Res. Commun. 52 (1973) 27-34
15. Belinsky M.G., Chen Z.S., Shchaveleva I., Zeng H., and Kruh G.D. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 62 (2002) 6172-6177
16. Bergo M.O., Leung G.K., Ambroziak P., Otto J.C., Casey P.J., and Young S.G. Targeted inactivation of the isoprenylcysteine carboxyl methyltrasferase gene causes mislocalization of K-Ras in mammalian cells. J. Biol. Chem. 275 (2000) 17605-17610
17. Blum R., and Kloog Y. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist. Updates 8 (2005) 369-380
18. Borst P., and Oude Elferink R.O. Mammalian ABC transporters in health and disease. Ann. Rev. Biochem. 71 (2002) 537-592
19. Bram E., Ifergan I., Shafran A., Berman B., Jansen G., and Assaraf Y.G. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother. Pharmacol. 58 (2006) 826-834
20. Chen L., Qi H., Korenberg J., Garrow T.A., Choi Y.J., and Shane B. Purification and properties of human cytosolic folylpoly-gamma-glutamate synthetase and organization, localization, and differential splicing of its gene. J. Biol. Chem. 271 (1996) 13077-13087
21. Chen Z.S., Lee K., Walther S., Raftogianis R.B., Kuwano M., Zeng H., and Kruh G.D. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62 (2002) 3144-3150
22. Chen Z.S., Hopper-Borge E., Belinsky M.G., Shchaveleva I., Kotova E., and Kruh G.D. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 63 (2003) 351-358
23. Chen Z.S., Robey R.W., Belinsky M.G., Shchaveleva I., Ren X.O., Sugimoto Y., Ross D.D., Bates S.E., and Kruh G.D. Transport of methotrexate, methotrexate polyglutamates and 17-beta-estradiol 17-(beta-d-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 63 (2003) 4048-4054
24. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., Bianco A.R., and Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6 (2000) 2053-2063
25. Cocconi G., Cinningham D., Van Custem E., Francois E., Gustavsson B., Van Hazel G., Kerr D., Possinger K., and Hietschold S.M. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J. Clin Oncol. 16 (1998) 2943-2952
26. Cole S.P., Bhardwaj G., Gerlach J., Mackie J.E., Grant C., Almquist K.C., Stewart A.J., Kurz E., Duncan A.M., and Deeley R.G. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258 (1992) 1650-1654
27. Cools J., Maertens C., and Marynen P. Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist. Updates 8 (2005) 119-129
28. Croop J.M., Tiller G.E., Fletcher J.A., Lux M.L., Raab E., Goldenson D., Son D., Arciniegas S., and Wu R.L. Isolation and characterization of a mammalian homolog of the Drosophila white gene. Gene 185 (1997) 77-85
29. Danø K. Active outward transport of daunomycin in resistant Ehrlich ascites. Biochim. Biophys. Acta 323 (1973) 537-592
30. Dean M., and Allikmets R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr. 33 (2001) 475-479
31. Deeley R.G., Westlake C., and Cole S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86 (2006) 849-899
32. Dembo M., Sirotnak F.M., and Moccio D.M. Effects of metabolic deprivation on methotrexate transport in L1210 leukemia cells: further evidence for separate influx and efflux systems with different energetic requirements. J. Membr. Biol. 78 (1984) 9-17
33. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., and Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95 (1998) 15665-15670
34. Drori S., Sprecher H., Shemer G., Jansen G., Goldman I.D., and Assaraf Y.G. Characterization of a human alternatively spliced truncated reduced folate carrier (RFC) increasing folate accumulation in parental leukemia cells. Eur. J. Biochem. 267 (2000) 690-702
35. Duch D.S., Banks S., Dev I.K., Dickerson S.H., Ferone R., Heath L.S., Humphreys J., Knick V., Pendergast W., Singer S., Smith G.K., Waters K., and Wilson H.R. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res. 53 (1993) 810-818
36. Elnakat H., and Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 56 (2004) 1067-1084
37. Elnakat H., and Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front. Biosci. 11 (2006) 506-519
38. Ewart G.D., and Howells A.J. ABC transporters involved in transport of eye pigment precursors in Drosophila melanogaster. Methods Enzymol. 292 (1998) 213-224
39. Farber S., Diamond L.K., Mercer R.D., Sylvester R.F., and Wolff V.A. Temporary remissions in acute leukemia produced by folic acid antagonist, 4-aminopeteroylglutamic acid (aminopterin). N. Engl. J. Med. 238 (1948) 787-793
40. Ferguson P.L., and Flintoff W.F. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J. Biol. Chem. 274 (1999) 16269-16279
41. Gangjee A., Zeng Y., Ihnat M., Warnke L.A., Green D.W., Kisliuk R.L., and Lin F.T. Novel 5-substituted, 2,4-diaminofuro[2,3]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Bioorg. Med. Chem. 13 (2005) 5475-5491
42. Gibbs D.D., Theti D.S., Wood N., Green M., Raynaud F., Valenti M., Forster M.D., Mitchell F., Bavetsias V., Henderson E., and Jackman A.L. BGC945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors. Cancer Res. 65 (2005) 11721-11728
43. Goldman I.D. Transport energetics of the folic acid analogue, methotrexate, in L1210 leukemia cells. Enhanced accumulation by metabolic inhibitors. J. Biol. Chem. 244 (1969) 3779-3785
44. Goldman I.D. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann. NY Acad. Sci. 186 (1971) 400-422
45. Gorlick R., Goker E., Trippet T., Waltham M., Banerjee D., and Bertino J.R. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med. 335 (1996) 1041-1048
46. Guo Y., Kotova E., Chen Z.S., Lee K., Hoppe-Borge E., Belinsky M.G., and Kruh G.D. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J. Biol. Chem. 278 (2003) 29509-29514
47. Hafkemeyer P., Dey S., Ambudkar S.V., Hrycyna C.A., Pastan I., and Gottesman M.M. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. Biochemistry 37 (1998) 16400-16409
48. Hakala M.T. On the nature of permeability of sarcoma-180 cells to amethopterin in vitro. Biochim. Biophys. Acta 102 (1965) 210-225
49. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., Von Pawel J., Gatzmeier U., Tsao T.C., PLess M., Muller T., Lim H.L., Desch C., Szondy K., Gervais R., Shaharyar S., Manegold C., Paul S., Paoletti P., Einhorn L., and Bunn Jr. P.A. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22 (2004) 1589-1597
50. Heijn M., Hooijberg J.H., Scheffer G.L., Szabo G., Westerhoff H.V., and Lankelma J. Anthracyclines modulate mutidrug resistance protein (MRP) mediated organic anion transport. Biochim. Biophys. Acta 1326 (1997) 12-22
51. Henderson G.B., and Zevely E.M. Transport routes utilized by L1210 cells for the influx and efflux of methotrexate. J. Biol. Chem. 259 (1984) 1526-1531
52. Henderson G.B., Tsuji J.M., and Kumar H.P. Characterization of the individual transport routes that mediate the influx and efflux of methotrexate in CCRF-CEM human lymphoblastic cells. Cancer Res. 46 (1986) 1633-1638
53. Honjo Y., Hrycna C.A., Yan Q.W., Medina-Perez W.Y., Robey R.W., van der Laan A., Litman T., Dean M., and Bates S.E. Acquired mutations in MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61 (2001) 6635-6639
54. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., Scheper R.J., Borst P., Pinedo H.M., and Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59 (1999) 2532-2535
55. Hooijberg J.H., Peters G.J., Assaraf Y.G., Kathmann I., Priest D.G., Bunni M.A., Veerman A.J., Scheffer G.L., Kaspers G.J., and Jansen G. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol. 65 (2003) 765-771
56. Hooijberg J.H., Jansen G., Assaraf Y.G., Kathmann I., Pieters R., Laan A.C., Veerman A.J.P., Kaspers G.J., and Peters G.J. Folate concentration dependent transport activity of the multidrug resistance protein 1 (ABCC1). Biochem. Pharmacol. 67 (2004) 1541-1548
57. Hopper-Borge E., Chen Z.S., Shchaveleva I., Belinsky M.G., and Kruh G.D. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. 64 (2004) 4927-4930
58. Huie M., Carducci M., Liu G., Wilding G., Marnocha R., Izquierda M., and Thomas J. Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. Am. J. Clin. Oncol. 28 (2005) 613-617
59. Ifergan I., Shafran A., Jansen G., Hooijberg J.H., Scheffer G.L., and Assaraf Y.G. Folate deprivation results in the loss of breast cancer resistance protein (ABCG2) expression: a role for BCRP in cellular folate homeostasis. J. Biol. Chem. 279 (2004) 25527-25534
60. Ifergan I., Jansen G., and Assaraf Y.G. Cytoplasmic confinement of breast cancer resistance protein (ABCG2) as a novel mechanism of folate deprivation. Mol. Pharmacol. 67 (2005) 1349-1359
61. Ito K., Oleschuk C.J., Westlake C., Vasa M.Z., Deeley R.G., and Cole S.P. Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of membrane transport activity. J. Biol. Chem. 276 (2001) 38108-38114
62. Ito K., Olsen S.L., Qiu W., Deeley R.G., and Cole S.P. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J. Biol. Chem. 276 (2001) 15616-15624
63. Jackman A.L., Taylor G.A., Gibson W., Kimbell R., Brown M., Calvert A.H., Judson I.R., and Hughes L.R. ICI D1694, a quinazoline antifolate thymidylate sytrhase inhibitor that is potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 51 (1991) 5579-5586
64. Jackman A.L., Kimbell R., Aherne G.W., Brunton L., Jansen G., Stephens T.C., Smith M.N., Wardkeworth J.M., and Boyle F.T. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res. 3 (1997) 911-921
65. Jackson R.C., Fry D.W., Boritzki T.J., Besserer J.A., Leopold W.R., Sloan B.J., and Elslager E.F. Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv. Enzyme. Regul. 22 (1984) 187-206
66. Jansen G., Westerhof G.R., Jarmuszewski M.J., Kathmann I., Rijksen G., and Schornagel J.H. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J. Biol. Chem. 265 (1990) 18272-18277
67. Jansen G., Mauritz R., Drori S., Sprecher H., Kathmann I., Bunni M., Priest D.G., Noordhuis P., Schornagel J.H., Pinedo H.M., Peters G.J., and Assaraf Y.G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem. 273 (1998) 30189-30198
68. Jansen G., Barr H.M., Kathmann I., Bunni M.A., Priest D.G., Noordhuis P., Peters G.J., and Assaraf Y.G. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools and intralysosomal drug sequestration. Mol. Pharmacol. 55 (1999) 761-769
69. Johnson J.M., Meiering E.M., Wright J.E., Pardo J., Rosowsky A., and Wagner C. NMR resolution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase. Biochemistry 36 (1997) 4399-4411
70. Johnson T.B., Nair M.G., and Galivan J. Role of folylpolyglutamate synthetase in the regulation of methotrexate polyglutamate formation in H35 hepatoma cells. Cancer Res. 48 (1988) 2426-2431
71. Kage K., Tsukahara S., Sugiyama T., Asada S., Ishikawa E., Tsuruo T., and Sugimoto Y. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through inhibition of S-S dependent homodimerization. Int. J. Cancer 97 (2002) 626-630
72. Kool M., van der Linden M., De Haas M., Scheffer G.L., De Vree J.M.L., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., Oude Elferink R.P.J., Baas F., and Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA 96 (1999) 6914-6919
73. Krishnamurthy P., and Schuetz J.D. Role of ABCG2/BCRP in biology and medicine. Ann. Rev. Pharmacol. Toxicol. 46 (2006) 381-410
74. Kruh G.D., and Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 22 (2003) 7537-7552
75. Kusuhara H., Han Y.-H., Shimoda M., Kokue E., Suzuki H., and Sugiyama Y. Reduced folate derivatives are endogenous substrates for cMOAT in rats. Am. J. Physiol. 275 (1998) G789-G796
76. Lee K., Klein-Szanto A.J.P., and Kruh G.D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 92 (2000) 1934-1940
77. Liani L., Rothem L., Bunni M.A., Smith C.A., Jansen G., and Assaraf Y.G. Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int. J. Cancer 103 (2003) 587-599
78. Lin B.F., Huang R.F., and Shane B. Regulation of folate and one-carbon metabolism in mammalian cells. III. Role of mitochondrial folylpoly-γ-glutamate synthetase. J. Biol. Chem. 268 (1993) 21674-21679
79. Liu X.Y., and Matherly L.H. Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochim. Biophys. Acta 1564 (2002) 333-342
80. Loo T.W., and Clarke D.M. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 33 (1994) 14049-14057
81. Masuda H., I'izuka M., Yamazaki Y., Nishigaki M., Kato R., Ni'inuma Y., Suzuki K., and Sugiyama Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 57 (1997) 3506-3510
82. Ma L., Krishnamachary N., and Center M.S. Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34 (1995) 3338-3343
83. Matherly L.H., and Goldman I.D. Membrane transport of folates. Vitamin Horm. 66 (2003) 403-456
84. Matin K., Jacobs S.A., Richards T., Wong M.K., Earle M., Evans T., Troetschel M., Ferri W., Friedland D., Pinkerton R., Volkin R., Wieland S., and Ramanathan R.K. A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. Am. J. Oncol. 28 (2005) 439-444
85. McBurney M.W., and Whitmore G.F. Isolation and biochemoical characterization of folate deficient mutants of Chinese hamster ovary cells. Cell 2 (1974) 173-182
86. McCloskey D.E., McGuire J.J., Russell C.A., Rowan B.G., Bertino J.R., Pizzorno G., and Mini E. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol. Chem. 266 (1991) 6181-6187
87. McGuire J.J., Russell C.A., and Balinska M. Human cytosolic and mitochondrial folylpolyglutamate synthetase are electrophoretically distinct. J. Biol. Chem. 275 (2000) 13012-13016
88. Miyake K., Mickley L., Litman T., Zhan Z., Robey R.W., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., and Bates S.E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells:demonstration of homology to ABC transport genes. Cancer Res. 59 (1999) 8-13
89. Molloy A.M., and Scott J.M. Folates and prevention of disease. Public Health Nutr. 4 (2001) 601-609
90. Moran R.G., Werkheiser W.C., and Zakrzewski S.F. Folate metabolism in mammlain cells in culture. I Partial characterization of the folate derivatives present in L1210 mouse leukemia cells. J. Biol. Chem. 251 (1976) 3569-3575
91. Moran R.G. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin. Oncol. 26 (1999) 24-32
92. Morgillo F., and Lee H.-Y. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist. Updates 8 (2005) 298-310
93. Nimec Z., and Galiven J. Regulatory aspects of the glutamylation of methotrexate in culture hepatoma cells. Arch. Biochem. Biophys. 226 (1983) 671-680
94. Ozvegy C., Litman T., Szakacs G., Nagy Z., Bates S.E., Varadi A., and Sarkadi B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun. 285 (2001) 111-117
95. Ozvegy C., Varadi A., and Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 mutidrug transporter. Modulation of substrate specificity by a point mutation. J. Biol. Chem. 277 (2002) 47980-47990
96. Özvegy-Lacka C., Cserepes J., Elkind N.B., and Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updates 8 (2005) 15-26
97. Pivot X., Walder S., Kelly C., Ruxer R., Totochaux J., Stern J., Belpomme D., Humblet Y., Domenge C., Clendeninn N., Johnston A., Penning C., and Schneider M. Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer. Ann. Oncol. 12 (2001) 1599-1959
98. Purcell W.T., and Ettinger D.S. Novel antifolate drugs. Curr. Oncol. Rep. 5 (2003) 114-125
99. Pizzorno G., Mini E., Corronello M., McGuire J.J., Mazzei T., Periti P., and Bertino J.R. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high dose treatment with this drug. Cancer Res. 48 (1998) 2149-2155
100. Polgar O., Robey R.W., Morisaki K., Dean M., Michejda C., Sauna Z.E., Ambudkar S.V., Tarasova N., and Bates S.E. Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 43 (2004) 9448-9556
101. Polgar O., Ozvegy-Laczka C., Robey R.W., Morisaki K., Okada M., Tamaki A., Toblos G., Elkind N.B., Yard Y., Dean M., Sarkadi B., and Bates S.E. Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization. Biochemistry 45 (2006) 5251-5260
102. Refsum H., Helland S., and Ueland P.M. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. Clin. Pharmacol. Ther. 45 (1989) 510-520
103. Rhee M.S., and Schneider E. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line. Biochem. Pharmacol. 69 (2005) 123-132
104. Riordan J., and Ling V. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J. Biol. Chem. 254 (1979) 12701-12705
105. Robey R.W., Honjo Y., Morisaki K., Nadjem T.A., Runge S., Risbood M., Poruchynsky M.S., and Bates S.E. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89 (2003) 1971-1978
106. Rosenquist T.H., Rataska S.A., and Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc. Natl. Acad. Sci. USA 93 (1996) 15227-15232
107. Rosowsky A., Wright J.E., Vadiya C.M., and Forsch R.A. The effect of side-chain, para-aminobenzoyl region, and B-ring mofdifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent N(α)-(4-amino-4-deoxypteroyl)-N-(δ)-hemiphtaloyl-l-ornithine. Pharmacol. Ther. 85 (2000) 191-205
108. Rothem L., Ifergan I., Kaufman Y., Priest D.G., Jansen G., and Assaraf Y.G. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cells. Biochem. J. 367 (2002) 741-750
109. Saier M.H., Beatty J.T., Goffeau A., Harley K.T., Heijne W.H., Huang S.C., Jack D.L., Jahn P.S., Lew K., Liu J., Pao S.S., Paulsen I.T., Tseng T.T., and Virk P.S. The major facilitator superfamily. J. Mol. Microbiol. Biotechnol. 1 (1999) 257-279
110. Sanghani P.C., and Moran R.G. Purification and characteristics of recombinant human folyl-poly-gamma-glutamate synthetase expressed at high levels in insect cells. Protein Exp. Purif. 18 (2000) 36-45
111. Saxena M., and Henderson G.B. MOAT4, a novel multispecific organic-anion transporter for glucuronides and mercapturates in mouse L1210 cells and human erythrocytes. Biochem. J. 320 (1996) 273-281
112. Saxena M., and Henderson G.B. Identification of efflux systems for large anions and anionic conjugates as the mediators of methorexate efflux in L1210 cells. Biochem. Pharmacol. 51 (1996) 974-982
113. Schirch V., and Strong W.B. Interaction of folylpolyglutamates with enzymes in one-carbon metabolism. Arch. Biochem. Biophys. 269 (1989) 371-380
114. Schornagel J.H., Verweij J., de Mulder P.H., Cognetti F., Vermorken J.B., Cappelaere P., Armand J.P., Wildiers J., de Graeff A., Clavel M., Sahmoud T., Kirkpatrick A., and Lefebvre J.L. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J. Clin. Oncol. 13 (1995) 1649-1655
115. Sczesny F., Hempel G., Boos G., and Blaschke G. Capillary electrophoretic drug monitoring of methotrexate and leucovorin and their metabolites. J. Chromatogr. B Biomed. Sci. Appl. 718 (1998) 177-185
116. Shafran A., Ifergan I., Bram E., Jansen G., Kathmann I., Peters G.J., Robey R.W., Bates S.E., and Assaraf Y.G. ABCG2 harboring the Gly482 mutation confers high level resistance to hydrophilic antifolates. Cancer Res. 65 (2005) 8414-8422
117. Shih J., Chen V.J., Gossett L.S., Gates S.B., McKellar W.C., Habeck L.L., Shackelford K.A., Mendelsohn L.G., Soose D.J., Patel V.F., Andis S.L., Bewley J.R., Rayl E.A., Moroson B.A., Beardsley G.P., Kohler W., Ratnam M., and Schultz R.M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57 (1997) 1116-1123
118. Sierra E.E., Brigle K.E., Spinella M.J., and Goldman I.D. pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Further evidence for a third route mediated at low pH. Biochem. Pharmacol. 53 (1997) 223-231
119. Sierra E.E., and Goldman I.D. Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function. Biochem. Pharmacol. 55 (1989) 1505-1512
120. Sirotnak F.M., DeGraw J.I., Moccio D.M., Samuels L.L., and Goutas L.J. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother. Pharmacol. 12 (1984) 18-25
121. Sirotnak F.M., and O'Leary D. The issues of transport multiplicity and energetics pertaining to methotrexate efflux in L1210 cells addressed by an analysis of cis- and trans-effects of inhibitors. Cancer Res. 51 (1991) 1412-1417
122. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., and Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6 (2000) 4885-4892
123. Spinella M.J., Brigle K.E., Freemantle S.J., Sierra E.E., and Goldman I.D. Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Biochem. Pharmacol. 52 (1996) 703-712
124. Stark M., Rothem L., Jansen G., Scheffer G.L., Goldman I.D., and Assaraf Y.G. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol. Pharmacol. 64 (2003) 220-227
125. Stokstad E.L.R. In: Picciano M.F., and Stokstad E.L.R. (Eds). Folic acid metabolism in health and disease (1990), Wiley-Liss, New York 1-21
126. Sullivan D.T., and Sullivan M.C. Transport defects as the physiological basis for eye color mutants of Drosophila melanogaster. Biochem. Genet. 13 (1975) 603-613
127. Sullivan D.T., Bell L.A., Paton D.R., and Sullivan M.C. Purine transport by Malphigian tubules of pteridine-deficient eye color mutants of Drosophila. Biochem. Genet. 17 (1979) 565-573
128. Sullivan D.T., Bell L.A., Paton D.R., and Sullivan M.C. Genetic and functional analysis of tryptophan transport in Malphigian tubules of Drosophila. Biochem. Genet. 18 (1980) 1109-1130
129. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Disc. 5 (2006) 219-234
130. Taylor E.C., Harrington P.J., Fletcher S.R., Beardsley G.P., and Moran R.G. Synthesis of the antileukemic agents 5,10-dideazaaminopetrin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin. J. Med. Chem. 28 (1985) 914-921
131. Tse A., and Moran R.G. Cellular folates prevent polyglutamylation of 5,10-dideazatetrahydrofolate. A novel mechanism of resistance to antimetabolites. J. Biol. Chem. 273 (1998) 25953-25960
132. van Aubel R.A.M.H., Smeets P.H.E., Peters J.G.P., Bindels R.J.M., and Russel F.G.M. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13 (2002) 595-603
133. van der Wilt C.L., Backus H.H., Smid K., Comijn L., Veerman G., Wouters D., Voom D.A., Priest D.G., Bunni M.A., Mitchell F., Jackman A.L., Jansen G., and Peters G.J. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res. 61 (2001) 3675-3681
134. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., Gatzemeier U., Boyer M., Emri S., Manegold C., Niyikiza C., and Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural meosthelioma. J. Clin. Oncol. 21 (2003) 2630-2636
135. Volk E.L., Rhode K., Rhee M., McGuire J.J., Doyle L.A., Ross D.D., and Schneider E. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 60 (2000) 3514-3521
136. Volk E.L., Farley K.M., Wu Y., Li F., Robey R.W., and Schneider E. Overexpression of wild type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62 (2002) 5035-5040
137. Volk E.L., and Schneider E. Wild type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate poluglutamate transporter. Cancer Res. 63 (2003) 5538-5543
138. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest. New Drugs 24 (2006) 37-77
139. Wielinga P., Hooijberg J.H., Gunnarsdottir S., Kathmann I., Reid G., Zelcer N., van der Born K., de Haas M., der Heijden I., Kaspers G., Wijnholds J., Jansen G., Peters G.J., and Borst P. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 65 (2005) 4425-4430
140. Wijnholds J., Mol C.A., van Deemter L., de Haas M., Scheffer G.L., Baas F., Beijnen J.H., Scheper R.J., Hatse S., De Clercq E., Balzarini J., and Borst P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA 97 (2000) 7476-7481
141. Winter-Vann A.M., Kamen B.A., Bergo M.O., Young S.G., Melnyk S., James S.J., and Casey P.J. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc. Natl. Acad. Sci. USA 100 (2003) 6529-6534
142. Yi P., Melnyk S., Pogribna M., Pogribny I.P., Hine R.J., and James S.J. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocsyteine and lymphocyte DNA hypomethylation. J. Biol. Chem. 275 (2000) 29318-29323
143. Zeng H., Chen Z.S., Belinsky M.G., Rea P.A., and Kruh G.D. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 61 (2001) 7225-7232
144. Zhang Y., Desharnais J., Marsilje T.H., Li C., Hedrick M.P., Gooljarsingh L.T., Tavassoli A., Benkovic S.J., Olson A.J., Boger D.L., and Wilson I.A. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR TFase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid. Biochemistry 42 (2003) 6043-6056
145. Zhao R., Seither R., Brigle K.E., Sharina I.G., Wang P.J., and Goldman I.D. Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine leukemia cells. J. Biol. Chem. 272 (1997) 21207-21212
146. Zhao R., Gao F., and Goldman I.D. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem. Pharmacol. 61 (2001) 857-865
147. Zhao R., Gao F., and Goldman I.D. Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. Am. J. Physiol. Cell. Physiol. 282 (2002) C1512-C1517
148. Zhao I.D., and Goldman I.D. Resistance to antifolates. Oncogene 22 (2003) 7431-7457